Pancreatic Cancer Research

ResearcherThe First Affiliated Hospital, Sun Yat-sen UniversityActive in the last 2 years

Zhide Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8200-7780; OpenAlex author ID A5019291446. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2023: 1 paper · 2024: 5 papers · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. Ferroptosis Suppression by the M6A Reader IGF2BP1 Underlies Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.77048↗
  2. CPT1A through succinylation regulates the CTCF/LINC01503‒91aa feedback loop to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.70776↗
  3. Auranofin facilitates gemcitabine sensitivity by regulating TXNRD1-related ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2025.218058↗
  4. Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202406714↗
  5. Platelet-Derived Growth Factor C Facilitates Malignant Behavior of Pancreatic Ductal Adenocarcinoma by Regulating SREBP1 Mediated Lipid Metabolism. First author DOI 10.1002/advs.202407069↗
  6. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy. Co-author DOI 10.1016/j.canlet.2024.216640↗
  7. Turning to immunosuppressive tumors: Deciphering the immunosenescence-related microenvironment and prognostic characteristics in pancreatic cancer, in which GL… Co-author DOI 10.1016/j.heliyon.2024.e36684↗
  8. N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance. Co-author DOI 10.1038/s41388-024-03092-3↗
  9. Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer. Co-author DOI 10.1016/j.ymthe.2022.11.004↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ying‐Qin Zhu · 9 shared papers, 2023–2026 · strength 1.97
  2. Mingjian Ma · 8 shared papers, 2024–2026 · strength 1.81
  3. Xiao-Yu Yin · 6 shared papers, 2024–2026 · strength 1.31
  4. Yin-Hao Shi · 6 shared papers, 2023–2024 · strength 1.13
  5. De-Liang Fang · 4 shared papers, 2024–2026 · strength 1.05
  6. Siyuan Lu · 4 shared papers, 2024–2026 · strength 1.05
  7. Jie‐Qin Wang · 5 shared papers, 2023–2024 · strength 0.92
  8. Xi‐Tai Huang · 4 shared papers, 2024 · strength 0.75
  9. Chen‐Song Huang · 2 shared papers, 2023–2024 · strength 0.35
  10. Xiao‐Yu Yin · 1 shared paper, 2026 · strength 0.28
  11. Xiao Yu Yin · 1 shared paper, 2024 · strength 0.22
  12. Wei Zhao · 1 shared paper, 2024 · strength 0.18
  13. Yue Huang · 1 shared paper, 2024 · strength 0.18
  14. Qi Liu · 1 shared paper, 2023 · strength 0.16
  15. Xiaoyu Yin · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.